Price
No data yet.
Social Signal Score
Analyst Ratings
26 analystsRevenue
$249.70M+14862.30%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Randy Teel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 246
- Beta
- 1.81
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 0.99
Financials
Revenue
$249.70M+14862.3%Net Income
$169.40MEBITDA
$159.80MFree Cash Flow
$-48.50MEPS (diluted)
$2.58Shares Outstanding (diluted)
65.70M+3362.4%Operating Expenses
$76.60MCash & Debt
$567.90MReturn of Capital
$0.00Revenue by Segment (annual)
$130.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $262.60M | $-80.80M | $-1.28 |
| 2024 | $263.40M | $-198.90M | $-2.77 |
| 2023 | $78.50M | $-367.30M | $-6.62 |
| 2022 | $131.40M | $-282.50M | $-5.31 |
| 2021 | $53.60M | $-191.00M | $-3.82 |
| 2020 | $25.90M | $-119.30M | $-3.02 |
| 2019 | $42.98M | $-70.29M | $-1.89 |
| 2018 | $14.32M | $-41.48M | $-1.31 |
| 2017 | $7.58M | $-24.05M | $-1.38 |
| 2016 | $6.67M | $-14.35M | $-7.56 |
Valuation
ARVNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-13.79%Social Signal Score
Mentions (9)
- Newszacks.com·1d ago·Neutral
Reasons Why Investors Should Consider Betting on Arvinas Stock ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.
View source ↗ - Newsglobenewswire.com·7d ago·Negative
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease – Data showed improvements in an objective measure of impaired eye movement associated with Parkinson's disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and changes in synaptic biomarkers –
View source ↗ - Newsglobenewswire.com·12d ago·Negative
…egrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders® NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease will be presented as late-breaking oral and poster presentations at the 2026 International Cong…
View source ↗ - Newsglobenewswire.com·14d ago·Negative
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the “Option Award”) and 42,388 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The Option…
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate – ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·40d ago·Negative
Arvinas to Participate in Upcoming Investor Conferences NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences:
View source ↗ - Newsglobenewswire.com·42d ago·Negative
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance wi…
View source ↗ - Newsseekingalpha.com·47d ago·Positive
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC platform. Despite Veppanu's approval for ESR1-mutated breast cancer, ARVN's share price remains near cash value, reflecting market skepticism about future revenues. ARVN's pipeline includes five early-stage programs and a Novartis-partnered asset, but high R&D costs and uncertain milestones temper near-term upside.
View source ↗
Earnings
Wed, Nov 4(in 3 weeks)
Consensus estimate $-0.87 per share
Typical surprise +36.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$2.58 vs $-0.37beat
- Tue, May 12$-0.90 vs $-0.95beat
- Tue, Feb 24$-1.10 vs $-0.55miss
- Wed, Nov 5$-0.48 vs $-0.75beat
- Wed, Aug 6$-0.84 vs $-0.87beat
- Thu, May 1$1.14 vs $-0.86beat
Estimates and results for ARVN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARVN officers and directors.
- Bought
- $495k
- Sold
- $2.3m
2 trades
33 trades
- Saik Andrewsold
- Cacace Angela Msold
- Teel Randysold
- Saik Andrewsold
- Loomis David Ksold
- Cacace Angela Msold
- Berkowitz Noahsold
- Teel Randysold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ARVN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.